AzTrials
AzTrials

Alveolar Bone LossPhase 3NCT04229719

Effect of Topical Melatonin Application on Dental Implant Osseointegration and Marginal Bone Level

A Phase 3 study testing N-acetyl-5-methoxytryptamine in people with Alveolar Bone Loss, run by University of Baghdad at 1 site in Iraq.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background: Melatonin (N-acetyl-5-methoxy-tryptamine) is an indoleamine synthesized and secreted by the pineal gland and other organs, such as the retina, bone marrow, and intestines in a circadian pattern. Some authors claimed that Melatonin induces bone formation, increase bone density, and bone implant contact. Read more about this study

Who is it for?
Ages 30 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Alveolar Bone Loss
What is being tested?
N-acetyl-5-methoxytryptamine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteIraq
Study dates
1 Nov 2019to 1 Nov 2020
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients have good oral hygiene.
  • Patients were periodontally healthy.
  • Patients had at least two missing teeth in the upper or lower jaw (canine to 1st molar area) indicated for the dental implant.

Who cannot join

  • Patients with any systemic diseases that influence bone healing such as osteoporosis and diabetes mellitus.
  • Fully edentulous.
  • Patients who had parafunctional habits.
  • Smokers.
  • Patients who were not able to follow the treatment protocol.
  • -

Trial locations and contacts

1 site in 1 country.

Zaid M Yasser, B.D.S contact

07810994677

zaid.al.aboodu@gmail.com

Saif S Saliem, M.S.C contact

+9647901529484

Iraq1 site, 1 recruiting
  • College of Dentistry / University of Baghdad

    Baghdad, 10047

    Recruiting

Other trials in Iraq

About this study

Official title: Effect of Topical Melatonin Application on Dental Implant Osseointegration and Marginal Bone Level (Clinical and Radiographic Evaluation)

Background: Melatonin (N-acetyl-5-methoxy-tryptamine) is an indoleamine synthesized and secreted by the pineal gland and other organs, such as the retina, bone marrow, and intestines in a circadian pattern. Some authors claimed that Melatonin induces bone formation, increase bone density, and bone implant contact. According to animal and human studies the melatonin can be used topically during implant placement to increase bone implant contact and reduce marginal bone loss.

Purpose: The aim of this study was to evaluate the effect of the topical administration of melatonin on osseointegration of dental implants and in minimize marginal bone loss.

Materials and Methods: Twenty single-piece endosseous implants (Dentium Co, Korea) will use to restore missing lower teeth from canine to first molar area. The study will be split-mouth technique, each patient serve as his own control (served into 2 groups), the study side (topical application of melatonin in the implant side), and the control side (no melatonin in the other implant side of the same patients).The primary and secondary stability of dental implant will be evaluated by periotest M device and measure bone level as baseline immediately after implant placement and after 6 months follow up by CBCT.

Read the detailed description

Melatonin (N-acetyl-5-methoxy-tryptamine) is an indoleamine synthesized and secreted by the pineal gland and other organs, such as the retina, bone marrow, and intestines in a circadian pattern. Extrapineal sites contribute poorly, or only upon specific stimuli to circulating melatonin. Melatonin influences numerous physiological actions that may be mediated by the binding of the indoleamine to membrane receptors in all tissues. Because of its lipophilic properties, melatonin passes through cell membranes to gain access to subcellular organelles, being capable to bind to some cytosolic proteins like kinase-C . Currently, melatonin is not considered a hormone in the classical sense of the term, because it is synthesized in several organs and does not exert effects on a specific target , but it is rather a powerful cell protector against molecular damage. For the synthesis of melatonin, the pineal cells take up tryptophan from the blood and, through hydroxylation and a decarboxylation process, turn it into serotonin. Serotonin is then converted into N-acetylserotonin through N-acetyltransferase and subsequently methylated to the final form of melatonin by the enzyme hydroxy indole-O-methyltransferase . In healthy individuals, the maximum secretion of melatonin occurs between midnight and 2 a.m., then it decreases to a minimum during the day. Melatonin has numerous physiological functions in different parts of the body, such as the control of circadian rhythms \, regulation of body temperature, and activation of the immune system.In the oral cavity, melatonin has been recognized as an important substance with paracrine effects on nearby cells, it also acts as an antioxidant and an anti-inflammatory and plays an important role in bone formation and in the reduction of bone resorption.

Osseointegration defined as a direct connection between living bone tissues and a titanium implant without any connective tissues. Osteoblasts are bone formative cells, and osteoclasts are bone resorptive cells. When these cells work together physiologically, the formation and resorption processes of bone tissue is known as bone remodelling. The remodeling of bone tissues is regulated by the action of systemic hormones (estradiol, parathyroid, growth, and melatonin) and by the bone marrow and osteoid matrix-derived growth factors.Insufficient bone quality and quantity can be seen frequently in elderly populations with atrophic and osteoporotic bones, and this situation stems from increased osteoclastic activity due to a reduction in osteoblastogenesis. In addition, local free radical concentrations in all body cells, including osteoblasts, can reduce osteoblastic activity in aged patients. This process could lead to a reduction in bone regeneration capacity. Melatonin can also suppress osteoclastogenesis, and therefore inhibit bone tissue resorption. In addition to this, in vitro research has reported that melatonin can increase osteoblast proliferation and differentiation. So was proposed that the local application of melatonin during surgical implant placement procedures would be an effective treatment technique for dental implant osseointegration. Worthy osseointegration is a prerequisite for dental implants. Optimal osseointegration depends on the formation of new bone around implants, which may be stimulated by the application of biomimetic agents. Considering the bone metabolism, melatonin acts directly on the osteoclast, a multinucleated cell, which resorbs the extracellular matrix through various mechanisms, including the production of free radicals. Moreover, in pre-osteoblast cultures from rats, melatonin, in a dose-dependent manner, promoted the development of bone sialoprotein and other protein bone markers, including alkaline phosphatase, osteopontin, and osteocalcin, and speeds up their period of differentiation into osteoblasts from the normal rate, which is 21 days, to 12 days, this reaction is mediated by the membrane receptors for the indole. Also, melatonin, may interfere with the function of the osteoclast and thereby inhibit bone resorption. conducted an experimental study using melatonin with dental implants in dogs. Two weeks after implant insertion, melatonin significantly increased all parameters of osteointegration. It has been observed that melatonin, increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. These data point towards an osteogenic effect of melatonin that may be of clinical importance, as it could be used as a therapeutic agent in situations in which bone formation would be advantageous, such as in the treatment of fractures or of osteoporosis.

Toxicology of Melatonin:- The physiological functions of the pineal hormone melatonin are extremely diverse. The functions include direct and indirect modulations of anti-oxidative defense, blood pressure, body temperature, cortisol rhythm, reproduction and immune function . Correspondingly, exogenous melatonin has been investigated as a treatment for a number of medical and surgical diseases, demonstrating encouraging results . In the USA, melatonin is available as an over-the-counter non-prescription drug. In most European countries, however, melatonin remains a prescription drug (Circadin) and has only been approved as a treatment for primary insomnia in people over 55 years of age. However, a recent Norwegian register study documented a 3- to 5-times increase in off-label use among children and adolescents in the time period 2004 to 2012 . Melatonin is generally considered safe, but the increasing clinical use with potentially increasing doses necessitates further investigations of the risks of both mild and serious adverse effects.

Periotest M device:-

Periotest device was developed to measure the damping characteristics of natural teeth and has been used to evaluate implant. It was developed by Schulte in 1983 to quantify TM , and then utilized by Teerlinck et al , to measure implant stability and to overcome destructive methods in measuring the implant stability like histologic analysis, tensional test, push-out/pull-out test and removal torque analysis. The (Classic/Wired) Periotest device has been the subject of several studies with generally favorable results. These results showed that the Periotest device generally demonstrated a high degree of repeatability and reliability. A wireless version of the Periotest (Periotest "M") has been introduced to the profession. According to information provided by the electronic page of the Periotest M /wireless device manufacturer (Medizintechnik Gulden, Modautal, Germany), Periotest M is simpler to perform an objective evaluation of an implant's stability compared to classic Periotest. In Periotest M wireless design, the user can benefit from maximum freedom of movement. The device can be used for taking measurements on a wide variety of implants, without the need for any special accessories, such as a smart peg . The Periotest has an important advantage against the others like the Osstell device: it can be applied directly to the implant superstructure .

The limitations of Periotest are the inability of the instrument to measure the mesiodistal mobility, the possible effect of position and angle of the rods on the measured value . The readings of PTV are from (-8 to +50) according to information provided by the device manufacturer (Medizintechnik Gulden, Modautal, Germany) .

Cone-beam computed tomography (CBCT):-

Cone-beam computed tomography (CBCT) is an imaging modality that offers significant advantages for the evaluation of implant patients . The field of view (FOV) is an important feature that describes the extent of the imaged volume from large FOV (greater than 15 cm) to medium FOV (8 to 15 cm) and limited FOV (less than 8 cm). Limited FOV units image a small area, delivering less radiation and producing a higher-resolution image . CBCT allows for defining with elevated accuracy the quality (cortical/medullar ratio) and the quantity (height and thickness) of bone available for the implant, providing the essential information of performing or not a preimplant bony graft . when compared to medical CT, CBCT can be recommended as a dose reducing technique for dental implant applications. The effective dose from CBCT examinations ranges from 13 µ Sv with the 3D Accuitomo CBCT machine using the 4 x4 cm FOV to 479 µ Sv with the CB Mercury CBCT machine . For comparison, the effective dose from one panoramic radiograph is approximately 10 to 14µSv. Furthermore, the exposure from a maxillomandibular medical CT ranges from 474 to 1160 µSv. The average background radiation in the United States is 3000 µSv (3 mSv) per year or 8 µSv per day . It is important to understand that every effort must be made to reduce the effective radiation dose to the patient. By using the smallest possible FOV, the lowest mA setting, the shortest exposure time, and a pulsed exposure mode of acquisition, it is possible to accomplish effective dose reduction to the patient.

Twenty single-piece endosseous implants (Dentium Co, Korea) will use to restore missing teeth in the upper or lower jaw (canine to 1st molars area) from both sides. The study will be split-mouth technique, each patient serves as his own control (served into 2 groups), the study side (topical application of melatonin in the implant side), and the control side (no melatonin in the other implant side of the same patients). According to the study reported by (Cutando et al., 2008) the estimated dose of melatonin required to enhance osseointegration of dental implant and minimize the marginal bone resorption is 1.2 mg of melatonin powder for each implant. CBCT for all patients before implant placement to determine bone density, dimension, and anatomical landmarks. Prior to surgery, all patients will instruct to use chlorhexidine 0.12% mouthwash as antiseptic. After local anesthesia, a mucoperiosteal flap will reflect. The manufacturer's instructions should be followed for the preparation of the implant osteotomy site. For the study side, 1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant. For the control side, no melatonin powder will be used and implants will be inserted directly in the prepared implant site. After dental implant installation, the gingival former will insert into the body of the fixture, then the Periotest M device will use to measure the primary stability of the DI fixture. After that, the gingival former will be removed and cover screw place and tightened into the fixture. Sutures will place after flap replacement. Patients should be instructed to use antibiotics amoxicillin 500mg and metronidazole 500mg 3 times/day for 5 days after surgical procedure, soft diet and proper oral hygiene measures. Also, CBCT immediately after implant placement to record baseline bone level, CBCT after 6 months follow up to measure marginal bone level around implant comparing with baseline measurement, and measure the secondary stability using periotest M device.

Being tested
N-acetyl-5-methoxytryptamine
Medical subject headings
Alveolar Bone Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • N-acetyl-5-methoxytryptamineDrug

    Also called Melatonin powder

    1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.

Study groups in NCT04229719
Study groupRoleWhat they receive
Melatonin groupExperimentalMelatonin powder (N-Acetyl-5-methoxytryptamine) 1.2mg topical application in osteotomy site.
Receives: Drug: N-acetyl-5-methoxytryptamine
Control groupNo interventionNo drug intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measuring marginal bone level

    measure crestal bone loss around dental implant using a cone-beam computed tomography (CBCT).

    Measured: 6 months .

Secondary outcomes (2)
  1. Measuring primary stability of the dental implant

    using periotest M device for measurement.

    Measured: 0 day.

  2. Measuring secondary stability of the dental implant

    using periotest M device for measurement.

    Measured: 6 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jan 2020
  2. Study start1 Nov 2019
  3. Primary completion1 Jun 2020
  4. Study completion1 Nov 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04229719
Sponsor's protocol ID
U0004TGZ
Status last verified
Oct 2020
First submitted
9 Jan 2020
Last updated
6 Oct 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing N-acetyl-5-methoxytryptamine in people with Alveolar Bone Loss, run by University of Baghdad at 1 site in Iraq.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Zaid M Yasser, B.D.S (07810994677, zaid.al.aboodu@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measuring marginal bone level (time frame: 6 months .). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in